PE20020289A1 - Compuestos con nucleos heterociclico-hidroximino-fluoreno y composiciones farmaceuticas que los contienen como inhibidores de las proteinas cinasas - Google Patents

Compuestos con nucleos heterociclico-hidroximino-fluoreno y composiciones farmaceuticas que los contienen como inhibidores de las proteinas cinasas

Info

Publication number
PE20020289A1
PE20020289A1 PE2001000808A PE2001000808A PE20020289A1 PE 20020289 A1 PE20020289 A1 PE 20020289A1 PE 2001000808 A PE2001000808 A PE 2001000808A PE 2001000808 A PE2001000808 A PE 2001000808A PE 20020289 A1 PE20020289 A1 PE 20020289A1
Authority
PE
Peru
Prior art keywords
compounds
protein kinases
heterociclico
fluoreno
hydroximino
Prior art date
Application number
PE2001000808A
Other languages
English (en)
Inventor
Rohit Kumar Duvadie
Wesley Kwan Mung Chong
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of PE20020289A1 publication Critical patent/PE20020289A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/14—Thiadiazoles; Hydrogenated thiadiazoles condensed with carbocyclic rings or ring systems

Abstract

SE REFIERE A COMPUESTOS CON NUCLEOS HETEROCICLICO-HIDROXIMINO-FLUORENO DE FORMULA I DONDE R5 Y R6 SON H, HALO, ALQUILO C1-C8, ALCOXI C1-C8, ARILO, HETEROARILO, ENTRE OTROS; X ES C-Y , N, DONDE Y ES H, HALO, NH2, NO2, ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO, ENTRE OTROS. SE REFIERE TAMBIEN A UN COMPUESTO DE FORMULA II DONDE R5 Y R6 SON H, HALO, ALQUILO C1-C8, ALCOXI C1-C8, ARILO, ENTRE OTROS; W ES O, S. SON COMPUESTOS PREFERIDOS (E/Z)-HIDROXIIMINO-3H-FLUORENO[2,3-d]IMIDAZOL, 2-AMINO-9(E/Z)-HIDROXIIMINO-3H-FLUORENO[2,3-d]IMIDAZOL, ENTRE OTROS. LOS COMPUESTOS DE FORMULA I Y II INHIBEN LA ACTIVIDAD DE LAS PROTEINA CINASAS Y SON UTILES PARA EL TRATAMIENTO DEL CANCER Y ENFERMEDADES ASOCIADAS CON LA ANGIOGENESIS Y PROLIFERACION CELULAR
PE2001000808A 2000-08-18 2001-08-14 Compuestos con nucleos heterociclico-hidroximino-fluoreno y composiciones farmaceuticas que los contienen como inhibidores de las proteinas cinasas PE20020289A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22480500P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
PE20020289A1 true PE20020289A1 (es) 2002-05-27

Family

ID=22842288

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000808A PE20020289A1 (es) 2000-08-18 2001-08-14 Compuestos con nucleos heterociclico-hidroximino-fluoreno y composiciones farmaceuticas que los contienen como inhibidores de las proteinas cinasas

Country Status (16)

Country Link
US (1) US6462060B2 (es)
EP (1) EP1309563B1 (es)
JP (1) JP2004506720A (es)
AR (1) AR032891A1 (es)
AT (1) ATE295354T1 (es)
AU (1) AU2001279090A1 (es)
BR (1) BR0113258A (es)
CA (1) CA2411924A1 (es)
DE (1) DE60110802T2 (es)
ES (1) ES2238463T3 (es)
GT (1) GT200100170A (es)
MX (1) MXPA03001452A (es)
PA (1) PA8525701A1 (es)
PE (1) PE20020289A1 (es)
SV (1) SV2003000603A (es)
WO (1) WO2002016326A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
JP4502641B2 (ja) * 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
EP2229955A1 (en) * 2003-10-16 2010-09-22 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment using the same
EP1812033A4 (en) * 2004-10-06 2009-11-11 Tiltan Pharma Ltd METHOD AND COMPOSITION FOR REINFORCE ANTI-ANGIOGENESIS THERAPY
SI1869020T1 (sl) 2005-03-29 2011-02-28 Icos Corp Derivati heteroaril uree, ki so uporabni za inhibicijo chk1
WO2007026720A1 (ja) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. 縮環ピラゾール誘導体

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625031A (en) 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
WO1997045397A1 (en) * 1996-05-30 1997-12-04 Hoechst Marion Roussel, Inc. Alkyloxyamino substituted fluorenones and their use as protein kinase c inhibitors
GB9621757D0 (en) 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
CN1278725A (zh) 1997-10-06 2001-01-03 巴斯福股份公司 茚并[1,2－c]－、萘并[1,2－c]－和苯并[6,7]芳庚并[1,2－c]吡唑类衍生物
YU22400A (sh) 1997-10-27 2003-08-29 Agouron Pharmaceuticals Inc. Supstituisana 4-amino-tiazol-2-i jedinjenja kao cdks inhibitori
ATE355841T1 (de) 1997-12-13 2007-03-15 Bristol Myers Squibb Co Verwendung von pyrazolo ( 3,4-b) pyridin als cyclin-abhängige kinase hemmer
AP1258A (en) 1998-02-26 2004-03-15 Aventis Pharma Inc 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines.
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
AU767409B2 (en) 1998-04-21 2003-11-06 Du Pont Pharmaceuticals Company 5-aminoindeno(1,2-C)pyrazol-4-ones as anti-cancer and anti-proliferative agents
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
EP1109823B1 (en) * 1998-09-08 2005-11-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
CN1335836A (zh) * 1998-11-06 2002-02-13 巴斯福股份公司 三环吡唑衍生物

Also Published As

Publication number Publication date
MXPA03001452A (es) 2004-05-04
US20020049238A1 (en) 2002-04-25
JP2004506720A (ja) 2004-03-04
ES2238463T3 (es) 2005-09-01
PA8525701A1 (es) 2002-04-25
BR0113258A (pt) 2003-07-15
ATE295354T1 (de) 2005-05-15
DE60110802D1 (de) 2005-06-16
SV2003000603A (es) 2003-01-13
US6462060B2 (en) 2002-10-08
GT200100170A (es) 2002-05-16
DE60110802T2 (de) 2005-10-06
EP1309563A1 (en) 2003-05-14
WO2002016326A1 (en) 2002-02-28
CA2411924A1 (en) 2002-02-28
EP1309563B1 (en) 2005-05-11
AU2001279090A1 (en) 2002-03-04
AR032891A1 (es) 2003-12-03

Similar Documents

Publication Publication Date Title
ECSP055680A (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
UY27834A1 (es) Compuestos de amidas de acido 3-amino-tieno(2,3-b) piiridino-2-carboxilico sustituido y procedimientos para prepararlos y sus usos.
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
ECSP055681A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
DE60314623D1 (de) Substituierte pyrazolopyrimidine
AR002267A1 (es) Compuestos de imidazol utiles para el tratamiento de patologias mediadas por citoquinas; composicion farmaceutica que los contiene; proceso para preparar dichos compuestos; uso del mismo para preparar dichas composiciones; compuestos intermediarios y procesos para su preparacion.
CR9929A (es) Nuevos compuestos
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
AR026187A1 (es) Heterociclos de nitrogeno biciclicos alquilamino substituidos
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
CL2011001360A1 (es) Compuestos derivados de imidazol[1,2-a]pirazin-8-amina, inhibidores de tirosina quinasa esplenica; composicion farmaceutica que comprende un compuesto; uso de los compuestos en la preparacion de medicamentos para el tratamiento de trastornos alergicos, enfermedades autoinmunes y enfermedades inflamatorias; y metodo in vitro.
AR018201A1 (es) Compuesto de mesilato de n-(3-etinilfenil)-6,7-bis-(2-metoxietoxi)-4-quinazolinamina, composiciones que los contienen y su uso de dichos compuestos para la preparacion de medicamentos.
PA8432901A1 (es) Compuestos de piridilpirrol
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
UY27924A1 (es) Compuestos tipo diarilureas fluoradas
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BRPI0413565B8 (pt) análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
ECSP045477A (es) COMPUESTOS DE AMIDAS DE ÁCIDO3-AMINO-TIENO[2,3-b]PIRIDINO-2-CARBOXÍLICO SUSTITUIDOY PROCEDIMIENTOS PARA PREPARARLOS Y SUS USOS.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed